[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 227, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 63, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 62, "title": "Co-Founder, CEO & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1009003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 61, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 734607, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 49, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}, {"maxAge": 1, "name": "Dr. Scott P. Bizily J.D., Ph.D.", "age": 52, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Translational Medicine Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Noriyuki  Kasahara M.D., Ph.D.", "age": 61, "title": "Chief Scientific Advisor & Member of Scientific Advisory Board", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 201288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.", "age": 63, "title": "Senior VP & Therapeutic Area Head of Pulmonology", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher Paul Simms", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julie  Clark M.D., M.S.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.67, "open": 8.73, "dayLow": 8.47, "dayHigh": 8.885, "regularMarketPreviousClose": 8.67, "regularMarketOpen": 8.73, "regularMarketDayLow": 8.47, "regularMarketDayHigh": 8.885, "payoutRatio": 0.0, "beta": 2.921, "forwardPE": -2.5987842, "volume": 399134, "regularMarketVolume": 399134, "averageVolume": 1158070, "averageVolume10days": 737930, "averageDailyVolume10Day": 737930, "bid": 6.28, "ask": 10.94, "bidSize": 2, "askSize": 2, "marketCap": 399306112, "fiftyTwoWeekLow": 2.235, "fiftyTwoWeekHigh": 9.96, "allTimeHigh": 55.11, "allTimeLow": 2.235, "priceToSalesTrailing12Months": 12100.186, "fiftyDayAverage": 6.7018, "twoHundredDayAverage": 4.869175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 129158096, "profitMargins": 0.0, "floatShares": 35704036, "sharesOutstanding": 46702467, "sharesShort": 4691697, "sharesShortPriorMonth": 4142441, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.1005, "heldPercentInsiders": 0.03849, "heldPercentInstitutions": 0.86961, "shortRatio": 7.39, "shortPercentOfFloat": 0.1046, "impliedSharesOutstanding": 46702467, "bookValue": 9.013, "priceToBook": 0.94862986, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -196144000, "trailingEps": -3.53, "forwardEps": -3.29, "enterpriseToRevenue": 3913.882, "enterpriseToEbitda": -0.598, "52WeekChange": -0.076673865, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 8.55, "targetHighPrice": 45.0, "targetLowPrice": 16.0, "targetMeanPrice": 32.66667, "targetMedianPrice": 36.0, "recommendationMean": 1.81818, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 293224992, "totalCashPerShare": 6.279, "ebitda": -215823008, "totalDebt": 23077000, "quickRatio": 8.456, "currentRatio": 8.746, "totalRevenue": 33000, "debtToEquity": 5.483, "revenuePerShare": 0.001, "returnOnAssets": -0.2518, "returnOnEquity": -0.38869998, "grossProfits": -170188992, "freeCashflow": -94590752, "operatingCashflow": -166388992, "revenueGrowth": 2.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -3963.7334, "financialCurrency": "USD", "symbol": "FDMT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1759532263, "regularMarketTime": 1759521601, "exchange": "NMS", "messageBoardId": "finmb_272879653", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1607697000000, "postMarketChangePercent": 0.0, "postMarketPrice": 8.55, "postMarketChange": 0.0, "regularMarketChange": -0.12, "regularMarketDayRange": "8.47 - 8.885", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1158070, "fiftyTwoWeekLowChange": 6.3150005, "fiftyTwoWeekLowChangePercent": 2.8255038, "fiftyTwoWeekRange": "2.235 - 9.96", "fiftyTwoWeekHighChange": -1.4099998, "fiftyTwoWeekHighChangePercent": -0.14156625, "fiftyTwoWeekChangePercent": -7.6673865, "earningsTimestamp": 1754915400, "earningsTimestampStart": 1762777800, "earningsTimestampEnd": 1762777800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.53, "epsForward": -3.29, "epsCurrentYear": -3.6937, "priceEpsCurrentYear": -2.314752, "fiftyDayAverageChange": 1.8482003, "fiftyDayAverageChangePercent": 0.2757767, "twoHundredDayAverageChange": 3.6808252, "twoHundredDayAverageChangePercent": 0.7559443, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-12-11", "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": -1.38408, "regularMarketPrice": 8.55, "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "displayName": "4D Molecular Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]